Wang et al showed that conjugate-mediated survivin-siRNA can efficiently target glioma tumors in vitro and in vivo, and that silencing survivin by this method prolonged the survival times of orthotopic tumor-bearing mice (44). The gene discussed is BIRC5; the disease is central nervous system cancer.